Simulect
Company: Novartis
Approval Status: Approved May 1998
Treatment for: acute organ transplant rejection
Areas: Endocrinology; Immunology/Infectious Diseases; Nephrology/Urology
| General Information | Mechanism of Action |
General Information
Other Useful Resources
Simulect has been approved for acute rejection episodes in renal transplant recipients.
Mechanism of Action
Simulect works by blocking the receptor for IL-2, a protein that simulates proliferation of T-lymphocytes, which play a key role in organ transplant rejection.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
